THIS EVENT IS NOW TAKING VIRTUALLY

PLEASE READ AND REGISTER HERE

SAVE THE DATE

21 – 22 January 2021

SCIENTIFIC WORKSHOP

Cape Town, South Africa

 “Design Approaches for Current and Future HIV Prevention Efficacy Trials”

Hosted by The Global HIV Vaccine Enterprise in partnership
with the HIV Vaccine Trials Network

HIV prevention is evolving rapidly with the roll out of new tools such as pre-exposure prophylaxis (PrEP) and treatment as prevention making a significant contribution towards controlling the epidemic. As a result, the design and conduct of the next generation of prevention trials is impacted and will be further affected by the outcomes of ongoing HIV prevention efficacy trials – including oral and injectable antiretrovirals, passively infused monoclonal antibodies, and HIV vaccines.

This scientific and technical workshop aims to continue from the first HIV Prevention Efficacy Trial Designs of the Future symposium, held in November 2018 in Seattle by the Fred Hutch and the NIAID, which led to a series of articles published in Statistical Communications in Infectious Diseases and a viewpoint in The Lancet HIV.

In this follow-up workshop, participants will reflect on more recent advances and challenges within the HIV prevention field and on the rationale and lessons learned for current HIV prevention designs. They will examine novel scientific approaches for establishing efficacy of new biologics in a future where all trial participants have access to effective prevention.

The two-day event will feature a series of talks given by biostatisticians and clinical trial experts, and will include panel discussions with clinicians, ethicists, regulators, community members and sponsors.

A series of articles, based on the talks given at the symposium, will be published in a selected high-impact journal.

Please share among your network.

More details of the day’s events and an agenda will be sent out closer to the date.

Organizing committee

• Holly Prudden, International AIDS Society, Geneva, Switzerland.
• Holly Janes, Fred Hutchinson Cancer Research Center, Seattle, USA.
• Deborah Donnell, Fred Hutchinson Cancer Research Center, Seattle, USA.
• Roger Tatoud, International AIDS Society, Geneva, Switzerland.
• Linda-Gail Bekker. Desmond Tutu HIV Centre, University of Cape Town (UCT), South Africa.

For immediate queries, please contact holly.prudden@iasociety.org.

The organization of this workshop is supported by a grant from the Bill and Melinda Gates Foundation and the US National Institutes of Health (NIH).